Scientists hunt for clues in blood to predict brain tumor treatment success

NCT ID NCT06222138

Recruiting now Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

Summary

This study aims to understand why some patients with a type of aggressive brain cancer (glioblastoma) respond better to a specific treatment called Tumor Treating Fields (TTFields). Researchers will collect blood and existing tumor tissue samples from 80 newly diagnosed patients to look for biological markers. The goal is to find clues that could help predict which patients will benefit most from this therapy in the future.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

IUCT-O
RECRUITING

Toulouse, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GLIOBLASTOMA